Research Outputs
Permanent URI for this communityhttps://hdl.handle.net/20.500.14288/2
Browse
532 results
Filters
Advanced Search
Filter by
Settings
Search Results
Publication Open Access #COVID19 and #Breastcancer: a qualitative analysis of tweets(Multidisciplinary Digital Publishing Institute (MDPI), 2022) Naganathan, G.; Cleland, J.; Reel, E.; Cil, T.; Bilgen, İdil; School of MedicineRapid and efficient communication regarding quickly evolving medical information was paramount for healthcare providers and patients throughout the COVID-19 pandemic. Over the last several years, social media platforms such as Twitter have emerged as important tools for health promotion, virtual learning among healthcare providers, and patient support. We conducted a qualitative thematic content analysis on tweets using the hashtags #BreastSurgery, #BreastCancer, #BreastOncology, #Pandemic, and #COVID19. Advocacy organizations were the most frequent authors of tweets captured in this dataset, and most tweets came from the United States of America (64%). Seventy-three codes were generated from the data, and, through iterative, inductive analysis, three major themes were developed: patient hesitancy and vulnerability, increased efforts in knowledge sharing, and evolving best practices. We found that Twitter was an effective way to share evolving best practices, education, and collective experiences among key stakeholders. As Twitter is increasingly used as a tool for health promotion and knowledge translation, a better understanding of how key stakeholders engage with healthcare-related topics on the platform can help optimize the use of this powerful tool.
Publication Metadata only 18F-FDG PET/CT imaging in a patient with a rare diagnosis of sarcomatoid malignant peritoneal mesothelioina(Lippincott Williams & Wilkins, 2013) Tokmak, Handan; Demirkol, Onur M.; Kaban, Kerim; N/A; Mandel, Nil Molinas; Dilege, Şükrü; Faculty Member; Faculty Member; School of Medicine; School of Medicine; 194197; 122573Malignant peritoneal mesothelioma is an uncommon but deadly disease arising from serosal surfaces of the peritoneum. Asbestos exposure is the most recognized risk factor. We report a case of diffuse, sarcomatoid malignant peritoneal mesothelioma who presented to the hospital with abdominal pain. The patient had an abdominal MRI scan as initial scanning which demonstrated nonspecific findings suspected of peritoneal carcinomatosis. The patient was admitted to our department for the metabolic characterization of the lesions with F-18-FDG PET/CT imaging and the diagnosis of the primary malignancy. F-18-FDG PET/CT imaging revealed diffusely increased metabolic activity throughout the peritoneum and the histopathological features were compatible with sarcomatoid malignant peritoneal mesothelioma.Publication Metadata only A case of pathologic complete response after neoadjuvant triplet chemotherapy for locally advanced colon cancer with mismatch repair enzyme proficiency(Via Medica, 2023) Kocak, Mehmet Zahid; Cakir, Murat; Kerimoglu, Ulku; Araz, Murat; Eryilmaz, Melek Karakurt; Artac, Mehmet; Yumuk, Perran Fulden; School of MedicinePatients with potentially resectable colon cancer and expected to have negative margins should undergo resection rather than neoadjuvant chemotherapy. Recent studies have suggested that neoadjuvant immunotherapy may be an option for tumors with mismatch repair enzyme deficiency (dMMR), but standard treatment for locally advanced colon cancer with mismatch repair enzyme proficiency (pMMR) is still unclear. A 37-year-old male patient was diagnosed with clinical stage IIIC (T4b N1a M0) transverse colon cancer. Mismatch repair proteins were proficient. After 3 cycles of oxaliplatin (85 mg/m(2), day 1), irinotecan (150 mg/m2, IV, day 1), leucovorin (200 mg/m(2), IV, day 1), and 5-fluorouracil (3000 mg/m(2), 46 hours of continuous infusion initiating from day 1), there was a remarkable reduction in the tumoral mass on the abdominal computed tomography. A right hemicolectomy was performed. A pathologic complete response was obtained. Although there is no consensus on which patients are suitable for neoadjuvant therapy in pMMR locally advanced colon cancer, triplet chemotherapy may be a reasonable option in selected patients.Publication Metadata only A case of secondary hemophagocytic lymphohistiocytosis (HLH) following incomplete kawasaki's disease (KD). Importance of distinguishing recurrent kd from HLH(2014) Kebudi, R.; Dindar, A.; Gürakan, F.; Devecioğlu, O.; Sözmen, Banu Oflaz; Faculty Member; School of Medicine; 198711N/APublication Metadata only A comperative molecular analysis of DNA damage response and apoptosis of malignant granulosa cells after exposure to gemcitabine and cisplatin(Bmj Publishing Group, 2019) Vatansever, Doğan; Bildik, Gamze; Taşkıran, Çağatay; Öktem, Özgür; Faculty Member; Teaching Faculty; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 193687; N/A; 134190; 102627Introduction/Background: We aimed to compare gemcitabine vs. cisplatin in terms of DNA damage response, viability/apoptosis of malignant granulosa cells. Methodology: Malignant granulosa tumour cell lines (COV434 and KGN) were used for the experiments. Cell viability, proliferation, DNA damage response and apoptosis were investigated using immunofluorescence staining and immunoblotting. Cell cycle analysis was carried out using flow cytometry. In vitro oestradiol and AMH productions were analysed by ECLIA method. Gemcitabine and cisplatin were used at four different concentrations corresponding to their therapeutic blood levels. Results: Gemcitabine treatment caused DNA damage, cellular stress, inhibited proliferation and activated cell cycle check-point sensors and induced apoptosis as shown by increased expression of g-histone H2AX, p-JNK, Chk-1/Chk-2, cleaved forms of PARP and caspase-3 in the asynchronous cells in a dose dependent manner. As a Result: the proliferation and in vitro AMH and oestrogen production of the cells were decreased at post-exposure 24h. In the cells synchronized at S phase gemcitabine significantly inhibited DNA synthesis and blocked their proliferation. Similar effects were also observed after cisplatin treatment. Exposure of the cells to gemcitabine at G2/M transition abolished the progression of mitosis, caused mitotic arrest and failure to exit mitosis as evidenced by the inhibition of Cyclin B degradation and absence of de-phosphorylation of cdc-2 at Tyr 15 residue. However, such an effect was not observed in the cells synchronized and treated with cisplatin at G2/M. Conclusion: These results may suggest that anti-metabolite chemotherapy drug gemcitabine might have anti-neoplastic actions on granulosa cell tumour.Publication Metadata only A nation-wide study determining psychosocial care skill perceptions of Turkish nurses working with cancer patients(Wiley, 2018) Yildirim, Nazmiye Kocaman; Inci, Figen; Hicdurmaz, Duygu; Fernandez, Ritin Santiago; Ozdemir, Sevgul; Ince, Aysegul; Yildirim, Yeter; N/A; Güner, Perihan; Faculty Member; School of Nursing; 101859N/APublication Metadata only A nation-wide study of Turkish oncology nurses' perceptions towards providing care for cancer patients(Wiley, 2018) Inci, Figen; Hicdurmaz, Duygu; Yildirim, Nazmiye Kocaman; Fernandez, Ritin Santiago; Ozdemir, Sevgul; Ince, Aysegul; Yildirim, Yeter; N/A; Güner, Perihan; Faculty Member; School of Nursing; 101859N/APublication Metadata only A platinum-blue complex exerts its cytotoxic activity via dna damage and induces apoptosis in cancer cells(Elsevier, 2016) Adiguzel, Z.; Ozalp-Yaman, S.; Celik, G.; Salem, S.; Cetin, Y. C.; Arda, N.; Acilan, C.; N/A; Önder, Tuğba Bağcı; Faculty Member; School of Medicine; 184359N/APublication Metadata only A population-based validation of the IGCCCG update consortium for survival in metastatic non-seminoma testis cancer(Oxford Univ Press, 2024) Incesu, Reha-Baris; Morra, Simone; Scheipner, Lukas; Barletta, Francesco; Baudo, Andrea; Garcia, Cristina Cano; Tappero, Stefano; Piccinelli, Mattia Luca; Tian, Zhe; Saad, Fred; Shariat, Shahrokh F.; de Cobelli, Ottavio; Terrone, Carlo; Chun, Felix K. H.; Carmignani, Luca; Briganti, Alberto; Ahyai, Sascha; Longo, Nicola; Tilki, Derya; Graefen, Markus; Karakiewicz, Pierre, I; Tilki, Derya; School of Medicine; Koç University HospitalBackground: In 2021, the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium reported improved overall survival (OS) rates in a modern cohort of metastatic non-seminoma testis cancer patients within each of the IGCCCG prognosis groups (96% in good vs. 89% in intermediate vs. 67% in poor), compared to the previous IGCCCG publication (92% in good vs. 80% in intermediate vs. 48% in poor). We hypothesized that a similar survival improvement may apply to a contemporary North-American population-based cohort of non-seminoma testis cancer patients. Patients and Methods: The Surveillance, Epidemiology, and End Results (SEER) database (2010-2018) was used. Kaplan-Meier plots and multivariable Cox regression models tested the effect of IGCCCG prognosis groups on overall mortality (OM). Results: Of 1672 surgically treated metastatic non-seminoma patients, 778 (47%) exhibited good vs. 251 (15%) intermediate vs. 643 (38%) poor prognosis. In the overall cohort, five-year OS rate was 94% for good prognosis vs. 87% for intermediate prognosis vs. 65% for poor prognosis. In multivariable Cox regression models predicting OM, intermediate (Hazard ratio [HR] 2.4, 95% confidence interval [CI] 1.4-3.9, P < 0.001) and poor prognosis group (HR 6.6, 95% CI 1.0-1.0, P < 0.001) were independent predictors of higher OM, relative to good prognosis group. Conclusions: The survival improvement reported by the IGCCCG Update Consortium is also operational in non-seminoma testis cancer patients within the most contemporary SEER database. This observation indicates that the survival improvement is not only applicable to centres of excellence, but also applies to other institutions at large.Publication Metadata only A Post-International Gastrointestinal Cancers’ Conference (IGICC) position statements(DOVE MEDICAL PRESS LTD, 2024) Yalcin, Suayib; Kaseb, Ahmed Omar; Peynircioglu, Bora; Cantasdemir, Murat; Hurmuz, Pervin; Dorul, Ahmet Bulent; Bozkurt, Murat Fani; Abali, Huseyin; Akhan, Okan; Simsek, Halis; Sahin, Berksoy; Aykan, Faruk N.; Yucel, Idris; Philip, Philip; Laçin, Şahin; Tellioğlu, Gürkan; Selçukbiricik, Fatih; Çil, Barbaros Erhan; School of Medicine; Koç University HospitalHepatocellular carcinoma (HCC), the most prevalent liver tumor, is usually linked with chronic liver diseases, particularly cirrhosis. As per the 2020 statistics, this cancer ranks 6th in the list of most common cancers worldwide and is the third primary source of cancer-related deaths. Asia holds the record for the highest occurrence of HCC. HCC is found three times more frequently in men than in women. The primary risk factors for HCC include chronic viral infections, excessive alcohol intake, steatotic liver disease conditions, as well as genetic and family predispositions. Roughly 40-50% of patients are identified in the late stages of the disease. Recently, there have been significant advancements in the treatment methods for advanced HCC. The selection of treatment for HCC hinges on the stage of the disease and the patient's medical status. Factors such as pre-existing liver conditions, etiology, portal hypertension, and portal vein thrombosis need critical evaluation, monitoring, and appropriate treatment. Depending on the patient and the characteristics of the disease, liver resection, ablation, or transplantation may be deemed potentially curative. For inoperable lesions, arterially directed therapy might be an option, or systemic treatment might be deemed more suitable. In specific cases, the recommendation might extend to external beam radiation therapy. For all individuals, a comprehensive, multidisciplinary approach should be adopted when considering HCC treatment options. The main treatment strategies for advanced HCC patients are typically combination treatments such as immunotherapy and anti-VEGFR inhibitor, or a combination of immunotherapy and immunotherapy where appropriate, as a first-line treatment. Furthermore, some TKIs and immune checkpoint inhibitors may be used as single agents in cases where patients are not fit for the combination therapies. As second -line treatments, some treatment agents have been reported and can be considered.